company background image
ACGN logo

Aceragen NasdaqCM:ACGN Stock Report

Last Price

US$0.38

Market Cap

US$3.2m

7D

-11.6%

1Y

-95.5%

Updated

23 Aug, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ACGN Stock Overview

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.

ACGN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Aceragen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aceragen
Historical stock prices
Current Share PriceUS$0.38
52 Week HighUS$16.00
52 Week LowUS$0.36
Beta1.14
1 Month Change-48.99%
3 Month Change-76.54%
1 Year Change-95.55%
3 Year Change-98.96%
5 Year Change-99.78%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07
Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31
When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Jan 13

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27
Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27
Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

Dec 15

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Nov 25
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Idera Pharma names new operations chief

Nov 17

Idera Pharmaceuticals EPS misses by $0.37

Oct 29

Shareholder Returns

ACGNUS BiotechsUS Market
7D-11.6%0.9%0.2%
1Y-95.5%11.0%28.1%

Return vs Industry: ACGN underperformed the US Biotechs industry which returned 6.3% over the past year.

Return vs Market: ACGN underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is ACGN's price volatile compared to industry and market?
ACGN volatility
ACGN Average Weekly Movement23.7%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ACGN's share price has been volatile over the past 3 months.

Volatility Over Time: ACGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198926John Taylorhttps://www.aceragen.com

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia.

Aceragen, Inc. Fundamentals Summary

How do Aceragen's earnings and revenue compare to its market cap?
ACGN fundamental statistics
Market capUS$3.20m
Earnings (TTM)-US$41.05m
Revenue (TTM)US$7.33m

0.4x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACGN income statement (TTM)
RevenueUS$7.33m
Cost of RevenueUS$15.40m
Gross Profit-US$8.06m
Other ExpensesUS$32.98m
Earnings-US$41.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.88
Gross Margin-110.00%
Net Profit Margin-559.86%
Debt/Equity Ratio1.3%

How did ACGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.